iPDT for Glioblastoma Multiforme Management: Dosimetric Enhancements

Median survival for Glioblastoma patients remains at around 15 months after surgery, radiation, and chemotherapy but varies widely between surgeons and centres. Interstitial Photodynamic Therapy (iPDT) mediated by ALA induced PpIX or other photosensitizers is investigated at various clinics. To enable iPDT treatment planning, photosensitizer transport characteristics needs to be known in order to optimize photoactivation. A method using contrast enhanced, functional magnetic resonance imaging, compartment modelling, spatial frequency domain imaging (SFDI) and inductively coupled plasma mass spectrometry (ICP-MS) is proposed to predict and validate the localization characteristics of two photosensitizers in murine Glioblastoma models.